Market News

Fusion Pharmaceuticals: Earnings Report Fall Short for Q4 of 2023 Fusion Pharmaceuticals: Earnings Report Fall Short for Q4 of 2023

by Ron Finklestien

Updated On: March 20, 2024 10:41 pm

FUSN stock - Fusion Pharmaceuticals Earnings Report Q4 2023

Source: iQoncept / Shutterstock

Fusion Pharmaceuticals (NASDAQ:FUSN) unveiled its figures for the fourth quarter of 2023.

The company’s earnings per share stood at -39 cents, trailing the analyst projection of -34 cents.
Notably, Fusion Pharmaceuticals did not generate any revenue during this fiscal period.

InvestorPlace Earnings, powered by TradeSmith data, streamlines the coverage of quarterly reports. The tool captures vital metrics such as earnings per share, revenue, and comparisons to analyst forecasts without human intervention. This swift dissemination ensures our readers are promptly informed with the latest financial updates. For corrections or discrepancies, kindly reach out to us at [email protected].

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/fusn-stock-earnings-fusion-pharmaceuticals-for-q4-of-2023/.